BR112016022438A2 - composto, composição farmacêutica compreendendo o mesmo, e seu uso - Google Patents

composto, composição farmacêutica compreendendo o mesmo, e seu uso

Info

Publication number
BR112016022438A2
BR112016022438A2 BR112016022438A BR112016022438A BR112016022438A2 BR 112016022438 A2 BR112016022438 A2 BR 112016022438A2 BR 112016022438 A BR112016022438 A BR 112016022438A BR 112016022438 A BR112016022438 A BR 112016022438A BR 112016022438 A2 BR112016022438 A2 BR 112016022438A2
Authority
BR
Brazil
Prior art keywords
compound
same
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
BR112016022438A
Other languages
English (en)
Other versions
BR112016022438B1 (pt
BR112016022438A8 (pt
Inventor
Tang Bing-Yu
B Olsen David
Fu Jianmin
M Girijavallabhan Vinay
Zhang Zhibo
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52824598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016022438(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of BR112016022438A2 publication Critical patent/BR112016022438A2/pt
Publication of BR112016022438A8 publication Critical patent/BR112016022438A8/pt
Publication of BR112016022438B1 publication Critical patent/BR112016022438B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12Triazine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14Pyrrolo-pyrimidine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112016022438-8A 2014-03-28 2015-03-26 Compostos inibidores da transcriptase reversa do hiv, sua composição farmacêutica e seu uso BR112016022438B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2014/074294 WO2015143712A1 (en) 2014-03-28 2014-03-28 4'-substituted nucleoside reverse transcriptase inhibitors
CNPCT/CN2014/074294 2014-03-28
PCT/US2015/022621 WO2015148746A1 (en) 2014-03-28 2015-03-26 4'-substituted nucleoside-derivatives as hiv reverse transcriptase inhibitors

Publications (3)

Publication Number Publication Date
BR112016022438A2 true BR112016022438A2 (pt) 2017-08-15
BR112016022438A8 BR112016022438A8 (pt) 2021-06-29
BR112016022438B1 BR112016022438B1 (pt) 2023-09-19

Family

ID=

Also Published As

Publication number Publication date
NZ724343A (en) 2020-02-28
TW201619180A (zh) 2016-06-01
WO2015143712A1 (en) 2015-10-01
CY1124829T1 (el) 2022-11-25
UA120758C2 (uk) 2020-02-10
US20180002366A1 (en) 2018-01-04
PL3122752T3 (pl) 2022-01-03
MY194635A (en) 2022-12-08
MX367058B (es) 2019-08-02
MD4812C1 (ro) 2023-01-31
IL247923B (en) 2021-01-31
GT201600201A (es) 2018-12-18
CN106795199B (zh) 2020-01-10
AU2017225090A1 (en) 2017-09-28
JP6182680B2 (ja) 2017-08-16
MD20160117A2 (ro) 2017-02-28
MA39809B1 (fr) 2021-10-29
RS62418B1 (sr) 2021-10-29
US20150274767A1 (en) 2015-10-01
GEP20197009B (en) 2019-08-12
SV2016005290A (es) 2018-05-03
PE20170197A1 (es) 2017-03-22
AU2015236018A1 (en) 2016-10-06
EA201691931A1 (ru) 2017-02-28
IL247923A0 (en) 2016-11-30
CL2016002414A1 (es) 2017-05-05
KR20160128437A (ko) 2016-11-07
ES2894228T3 (es) 2022-02-14
NI201600145A (es) 2016-10-27
EA031476B1 (ru) 2019-01-31
EP3122752A1 (en) 2017-02-01
CR20160451A (es) 2016-12-06
HUE056913T2 (hu) 2022-03-28
AU2015236018B2 (en) 2017-09-28
PT3122752T (pt) 2021-10-20
US9777035B2 (en) 2017-10-03
MX2016012659A (es) 2016-12-14
AR099788A1 (es) 2016-08-17
DOP2016000265A (es) 2017-04-30
HRP20211622T1 (hr) 2022-03-04
DK3122752T3 (da) 2021-10-25
BR112016022438A8 (pt) 2021-06-29
KR101961009B1 (ko) 2019-03-21
WO2015148746A1 (en) 2015-10-01
CN106795199A (zh) 2017-05-31
JO3636B1 (ar) 2020-08-27
AP2016009482A0 (en) 2016-10-31
MA39809A (fr) 2021-04-07
CA2943792A1 (en) 2015-10-01
MD4812B1 (ro) 2022-06-30
PH12016501897A1 (en) 2016-12-19
TWI660967B (zh) 2019-06-01
LT3122752T (lt) 2021-11-10
ECSP16085206A (es) 2017-08-31
CA2943792C (en) 2020-02-25
AU2017225090B2 (en) 2018-08-09
SI3122752T1 (sl) 2021-11-30
SG11201608031PA (en) 2016-10-28
EP3122752B1 (en) 2021-08-25
JP2017512797A (ja) 2017-05-25

Similar Documents

Publication Publication Date Title
BR112016030787A2 (pt) entidade química, composição farmacêutica e seu uso
NO2023013I1 (no) Combination of foslevodopa and foscarbidopa, each in all forms protected by the basic patent
BR112016015706A2 (pt) composto, uso do mesmo e composição farmacêutica
CL2018000813A1 (es) Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso.
CL2016002364A1 (es) Indazol-3-carboxamidas 5-sustituidas y preparación y uso de las mismas
BR112016020199A2 (pt) Composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
BR112016027722A2 (pt) compostos contendo grupo autoimulativo e seu uso
MA50674A (fr) Benzamides substitués 1,3-thiazol-2-yl
DK3297605T3 (da) Topiske, farmaceutiske sammesætninger
BR112016030968A2 (pt) análogos de pridopidina, preparação e uso destes
CL2016002569A1 (es) Anticuerpos, composiciones farmacéuticas y usos de los mismos
BR112016023628A2 (pt) composições farmacêuticas.
BR112018000390A2 (pt) fenoxihalogenofenilamidinas e o uso dessas como fungicidas
DK3255042T3 (da) Heterocyklisk forbindelse og farmaceutisk sammensætning omfattende samme
DK3223796T3 (da) Farmaceutiske sammensætninger, fremstilling og anvendelser deraf
DK3554534T3 (da) Farmaceutisk sammensætning omfattende insulin
DK3275452T3 (da) Farmaceutisk sammensætning med silibinin
BR112016019868A2 (pt) proteínas de fusão tatk-cdkl5, composições, formulações, e seu uso
DK3411008T3 (da) Sammensætninger omfattende aktive solbeskyttelsesmidler med polyhydroxyfulleren
BR112014025416A2 (pt) AGENTES ANTIMALÁRICOS, COMPOSIÇÃO FARMACEUTICA COMPREENDENDO-OS E USO Dos MESMOS.
CL2018000403A1 (es) Compuestos para uso en aplicaciones antibacterianas.
DK3229843T3 (da) Farmaceutisk sammensætning, præparat og anvendelser deraf
BR112016027383A2 (pt) Derivados de naftiridinadiona, seus usos, composição farmacêutica e combinação
BR112018005299A2 (pt) 1,1-difeniletilenos substituídos com alquenilfenoxi, processos para sua preparação e seu uso
BR112016021231A2 (pt) derivados de hexose, preparação e uso destes.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: MERCK SHARP AND DOHME LLC (US)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/03/2015, OBSERVADAS AS CONDICOES LEGAIS